RAMANTAMIG
UNII L97FGF546Q

Substance Identification & Data

This profile provides standardized clinical and technical data for Ramantamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) L97FGF546Q.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2988886-91-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

L97FGF546Q

CAS Registry Number

2988886-91-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RAMANTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C216004

National Cancer Institute reference terminology for clinical and research data.

INN ID

13340

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-51

Identifier assigned by the United States Adopted Names Council.

Substance Type

Ramantamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ramantamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Ramantamig

Common Names & Synonyms

H-gamma1 heavy chain anti-CD3E fused to a scFvkh anti-GPRC5D (1-721) [Hgamma1 heavy chain anti-CD3E Homo sapiens (1-450) [VH (Homo sapiens IGHV6-1*01 (88.1%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [10.9.10] (26-35.53-61.100-109)) (1-120)-Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83 CH3 R115, F116 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237), L1.2>A (238), D27>S (268) (234-343), CH3 E12 (359), M14 (361), T22>S (369), L24>A (371), Y86>V (410), H115>R (438), Y116>F (439) (344-448), CHS (449-450)) (121-450)] -20-mer tetrakis(tetraglycyl-seryl) linker (451-470) -scFvkh anti-GPRC5D Homo sapiens (471-721) [V-KAPPA (Homo sapiens IGKV2-24*01 (99.0%) -IGKJ2*02 (100%), CDR-IMGT [11.3.9] (497-507.525-527.564-572)) (471-582) -20-mer (GGSEGKSSGSGSESKSTGGS) linker (583-602) -VH (Homo sapiens IGHV2-26*04 (93.9%) -IGHD -IGHJ6*01 (100%), CDR-IMGT [10.7.11] (628-637.655-661.700-710)) (603-721)]]; (223-215')-disulfide with L-lambda2 light chain anti-CD3E Homo sapiens (1'-216') [V-LAMBDA (Homo sapiens IGLV2-23*02 (84.8%) -IGLJ2*01 (90.9%), CDR-IMGT [9.3.10] (26'-34'.52'-54'.91'-100')) (1'-110') -Homo sapiens IGLC2*01 (100%) (C-LAMBDA2) (111'-216')]; fused heavy chain scFvkh-G1(h-CH2-CH3) anti-TNFRSF17 Homo sapiens (1''-484'') [scFvkh anti-TNFRSF17 Homo sapiens (1''-252'') [V-KAPPA (Homo sapiens IGKV3-20*01 (94.8%) -IGKJ2*01 (100%), CDR-IMGT [7.3.10] (27''-33''.51''-53''.90''-99'')) (1''-109'') -20-mer (GGSEGKSSGSGSESKSTGGS) linker (110''-129'') -[VH (Homo sapiens IGHV3-23*01 (100%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.8.16] (155''-162''.180''-187''.226''-241'')) (130''-252'')] -Homo sapiens IGHG1*03v h-CH2-CH3-CHS, nG1m1 CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v32 CH3 W22 (knob), 15-G1v37 hinge S5 [(hinge 1-15 C5>S(257'') (253''-267''), CH2 L1.3>A (271''), L1.2>A (272''), D27>S (302'') (268''-377''), CH3 E12 (393''), M14 (395''), T22>W (403'') (378''-482''), CHS (483''-484'')) (253''-484'')]]; dimer (229-263'': 232-266'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Immunoglobulin G1, trispecific, [237-alanine,238-alanine,268-serine,369-serine,371-alanine,410-valine,438-arginine,439-phenylalanine], anti-(human CD3 antigen ε-chain) (human monoclonal BGCB491 γ1-chain) fusion protein with peptide linker (GGGGS)4 fusion protein with immunoglobulin anti-(human G protein-coupled receptor GPRC5D) (human monoclonal BGCB491 single-chain variable region fragment VL-peptide linker (synthetic 20-amino acid)-VH), disulfide with human monoclonal BGCB491 λ-chain, (229→263′),(232→266′)-bis(disulfide) with immunoglobulin anti-(human Tumor necrosis factor receptor superfamily protein TNFRSF17) (human monoclonal BGCB491 single-chain variable region fragment VL-peptide linker (synthetic 20-amino acid)-VH) fusion protein with immunoglobulin G1 [5′-serine,19′-alanine,20′-alanine,50′-serine,151′-tryptophan] (human γ-1 chain C-region C-terminal fragment)

JNJ 79635322 [WHO-DD]

RAMANTAMIG [USAN]

immunoglobulin (H-gamma1-scFvkh_L-lambda2)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], anti-[Homo sapiens GPRC5D (G protein-coupled receptor class C group 5 member D)] and anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)], Homo sapiens monoclonal antibody; trispecific, trivalent; H-gamma1 heavy chain anti-CD3E fused to a scFvkh anti-GPRC5D (1-721) [H-gamma1 heavy chain anti-CD3E Homo sapiens (1-450) [VH (Homo sapiens IGHV6-1*01 (88.1%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [10.9.10] (26-35.53-61.100-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83 CH3 R115, F116 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237), L1.2>A (238), D27>S (268) (234-343), CH3 E12 (359), M14 (361), T22>S (369), L24>A (371), Y86>V (410), H115>R (438), Y116>F (439) (344-448), CHS (449-450)) (121-450)] -20-mer tetrakis(tetraglycyl-seryl) linker (451-470) -scFvkh anti-GPRC5D Homo sapiens (471-721) [V-KAPPA (Homo sapiens IGKV2-24*01 (99.0%) -IGKJ2*02 (100%), CDR-IMGT [11.3.9] (497-507.525-527.564-572)) (471-582) -20-mer (GGSEGKSSGSGSESKSTGGS) linker (583-602) -VH (Homo sapiens IGHV2-26*04 (93.9%) -IGHD -IGHJ6*01 (100%), CDR-IMGT [10.7.11] (628-637.655-661.700-710)) (603-721)]]; (223-215')-disulfide with L-lambda2 light chain anti-CD3E Homo sapiens (1'-216') [V-LAMBDA (Homo sapiens IGLV2-23*02 (84.8%) -IGLJ2*01 (90.9%), CDR-IMGT [9.3.10] (26'-34'.52'-54'.91'-100')) (1'-110') -Homo sapiens IGLC2*01 (100%) (CLAMBDA2) (111'-216')]; fused heavy chain scFvkh-G1(h-CH2-CH3) anti-TNFRSF17 Homo sapiens (1''-484'') [scFvkh anti-TNFRSF17 Homo sapiens (1''-252'') [V-KAPPA (Homo sapiens IGKV3-20*01 (94.8%) -IGKJ2*01 (100%), CDR-IMGT [7.3.10] (27''-33''.51''-53''.90''-99'')) (1''-RAMANTAMIG October 29, 2025 N25 Page 2 of 3 240 109'') -20-mer (GGSEGKSSGSGSESKSTGGS) linker (110''-129'') -[VH (Homo sapiens IGHV3-23*01 (100%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.8.16] (155''-162''.180''-187''.226''-241'')) (130''-252'')] -Homo sapiens IGHG1*03v h-CH2-CH3-CHS, nG1m1 CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v32 CH3 W22 (knob), 15-G1v37 hinge S5 [(hinge 1-15 C5>S (257'') (253''-267''), CH2 L1.3>A (271''), L1.2>A (272''), D27>S (302'') (268''-377''), CH3 E12 (393''), M14 (395''), T22>W (403'') (378''-482''), CHS (483''-484'')) (253''-484'')]]; dimer (229-263'': 232-266'')-bisdisulfide

ramantamig [INN]